Skip to content

Glaukos GKOS Interest coverage

Interest coverage at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
24.5×-1.7×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
75.6×-4.5×
Boston Scientific logo
Boston ScientificBSX
10.6×+1.7×
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
5.3×-1.8×

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Calculated from Glaukos’s reported figures.

Based on trailing twelve months.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's interest coverage?
Glaukos (GKOS) reported interest coverage of -43.2× in Q1 2026.
How has Glaukos's interest coverage changed year-over-year?
Glaukos's interest coverage decreased by 222.4% year-over-year, from -13.4× to -43.2×.
What is the long-term trend for Glaukos's interest coverage?
Over 5 years (2020 to 2025), Glaukos's interest coverage has grown at a 37.5% compound annual growth rate (CAGR), from -8.8× to -43.1×.
What does interest coverage mean?
Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.